Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05135858
Other study ID # APHP201186
Secondary ID 2021-000210-42
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 15, 2022
Est. completion date July 31, 2025

Study information

Verified date October 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Caroline HOUILLIER, MD
Phone 01 42 16 41 60
Email caroline.houillier@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High dose intravenous Methotrexate (HD-MTX) is the key drug in the treatment of primary central nervous system lymphoma (PCNSL). HD-MTX is usually delivered with time interval ranging from 10 to 21 days. Reduction of injection time interval is limited by MTX renal excretion and systemic toxicity. Glucarpidase (CPG2) is a recombinant bacterial rescue enzyme that cleaves circulating MTX into inactive metabolites, reducing plasma MTX concentrations within few minutes. The research hypothesis is that CPG2 used after HD-MTX injection allows to reduce time interval between MTX injections, increase dose intensity of the chemotherapy, reduce systemic toxicity and duration of hospitalization.


Description:

Open-label multicenter Phase I dose finding trial based on 3+3 escalation design. The phase I will follow a standard "3+3" dose level escalation design with reduced time interval of HD-MTX injections at fixed dose of HD-MTX to establish the minimum tolerated time interval. HD-MTX (methotrexate) is administered intravenously at the dose 3.5 g/m² (body surface area capped at 2 m2) over 2 to 3 hours, followed at H24 by glucarpidase with a 3 different MTX administration intervals: 8 days, 6 days, and 5 days. Treatments will be continued for a maximum of 6 injections until disease progression, unacceptable toxicity, or investigator's/patient's decision. Three dose levels could be explored under toxicity restrictions, where the dose combination for each cohort of three subjects will be determined by 3+3 escalation rule. Three schedule dose levels will be : every 8 days, every 6 days and every 5 days. The starting schedule dose of HD-MTX will be one administration of HD-MTX every 8 days for 6 injections. Dose of MTX will be fixed and will not be modified. No skipping of the dose level will be allowed. No intra-patient dose escalation is allowed. The DLT evaluation period begins with the first dose of methotrexate and ends at the beginning of the 25th day after the first MTX infusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date July 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Cerebral relapse of primary CNS lymphoma (any line) 2. Pathological diagnosis of diffuse large B cell lymphoma (or cytological diagnosis in the CSF or in the vitreous) at initial diagnosis (not mandatory at the time of the present relapse) 3. Absence of any systemic involvement confirmed by full body CT scan and/or FDG-PET scan 4. Age=18 years 5. HD-MTX based chemotherapy in first line treatment, with complete response lasting at least 6 months after the end of the 1st line treatment 6. No administration of other anticancer therapy within the 3 weeks prior to inclusion 7. Karnofsky performance status (KPS) = 50 8. Adequate haematological, renal and hepatic function (adequate Laboratory Parameters within 21 days): 1. Absolute neutrophil count (ANC) >1000/mm3 2. Platelets > 100,000/mm3 independent of transfusion support 3. Alanine aminotransferase and aspartate aminotransferase = 3 x upper limit of normal (ULN) and/or total bilirubin = 1,5x ULN, unless related to Gilbert's or Meulengracht disease 4. Estimated Glomerular Filtration Rate = 60 mL/min/1.73m2) (MDRD) 9. All non-hematological adverse events (AEs) related to prior therapy completely resolved or improved to Grade 1-2 (except for alopecia or fatigue). 10. Written informed consent, which could be signed by the trustworthy person or close relatives in case the neurologic status of the patient does not allow him to sign. In case the patient is unable to sign the consent at baseline, but his neurological status improves during the treatment, he will be asked to give his written informed "follow-up" consent Exclusion Criteria: 1. Positive HIV serology 2. Active viral infection with Hepatitis B or C virus 3. Preexisting immunodeficiency (organ transplant recipient) 4. Relevant congestive heart failure interfering with hydration 5. Isolated CNS relapse of systemic non-Hodgkin's lymphoma (NHL) 6. Pregnancy or lactation. An effective contraception is mandatory for patients (men and women of childbearing potential) all along the study participation and during at least 6 months after the end of MTX. Men must not donate sperm all along the study participation and during at least 6 months after the end of MTX. 7. Third space (i.e. pleural effusion, ascites, extended oedema). 8. Obesity (body mass index >30 kg/m2). 9. Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer 10. Absolute contraindication to MTX or leucovorin 11. Previous use of carboxypeptidase for delayed MTX excretion and kidney dysfunction after HD-MTX 12. No social security affiliation 13. Persons under legal protection (tutorship or curatorship) or safety measure 14. Participation in any other clinical trial (Jardé 1 and 2) either 1 month prior to or during this study.

Study Design


Related Conditions & MeSH terms

  • Lymphoma
  • Primary Central Nervous System Lymphoma

Intervention

Drug:
Glucarpidase
Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
Methotrexate (MTX)
MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration

Locations

Country Name City State
France Hôpital Pitié-Salpêtrière Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris BTG International Inc.

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The occurrence of a dose schedule limiting toxicity (DLT) defined as any of the following events assessed as related or possibly related to methotrexate:
Any grade V toxicity (according to NCI-CTCAE v 5.0)
Grade IV non-haematological toxicity excluding fatigue, alopecia, nausea, vomiting (according to NCI-CTCAE v 5.0)
Creatinine > 3 X baseline (grade III toxicity according to NCI-CTCAE v 5.0)
Grade IV thrombopenia, grade III thrombopenia with bleeding, grade IV neutropenia or grade III neutropenia with fever,lasting > 3 days (according to NCI-CTCAE v 5.0)
Delay in MTX administration > 36 hours due to any adverse effect.
25th day after the first injection of methotrexate
Secondary Frequency and grading of adverse event according to NCI-CTCAE v5.0 through study completion, an average of 4 months
Secondary Mean score of neurocognition assessed by neuropsychological testing at baseline and within the - Neurocognition assessed by neuropsychological testing at baseline and within the 3 months after the end of HD-MTX treatment 3 months after the end of HD-MTX treatment
Secondary Overall response rate according to IPCG criteria After 3 cycles (each cycle is 5, 6 or 8 days), at the end of treatment (up to 48 days) and at 3 months after the end of treatment (up to 48 days)
Secondary Mean of dosages of MTX and its metabolites in the blood, urine and cerebrospinal fluid (CSF) At the first and the third cycles (each cycle is 5, 6 or 8 days)
Secondary Mean of dosage of anti-glucarpidase antibodies At baseline, then prior to each CPG2 dose, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment.(up to 48 days)
Secondary Mean global score of quality of life assessment measured with EORTC QLQ-C30 scale At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)]
Secondary Mean global score of quality of life assessment measured with Brain Module (BM 20) At baseline, at the end of HD-MTX treatment (up to 48 days) and at 3 months after the end of HD-MTX treatment (up to 48 days)
Secondary Median duration of treatment-related hospitalization in acute care unit Defined as the cumulative time from start of the HD MTX protocol (including the pre-hydration) to its elimination From day 1 until discharge from hospital, an average of 4 to 7 weeks
Secondary Mean of dosage of CSF IL-10 At baseline and at the end of the treatment (up to 48 days)
Secondary Median duration of hospitalization during the treatment Duration of treatment-related hospitalization in acute care unit From day 1 until end of the treatment (up to 48 days)
See also
  Status Clinical Trial Phase
Recruiting NCT04083066 - Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma Phase 4
Active, not recruiting NCT02313389 - Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Phase 3
Recruiting NCT02657785 - Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Phase 2/Phase 3
Recruiting NCT02836158 - Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Phase 2/Phase 3
Recruiting NCT06445257 - A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL N/A
Completed NCT01421524 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Phase 1
Active, not recruiting NCT00863460 - Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients Phase 2
Active, not recruiting NCT05036577 - A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL Phase 1
Recruiting NCT04514393 - Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Phase 2
Not yet recruiting NCT04066920 - IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL Phase 2
Recruiting NCT03733327 - BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Phase 2/Phase 3
Recruiting NCT00455286 - a Phase II Study in Primary Central Nervous System Lymphoma Phase 2
Completed NCT02301364 - Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Phase 2
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT02669511 - PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT04457869 - A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) Phase 2
Recruiting NCT02655744 - Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
Recruiting NCT02399189 - MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Phase 2
Recruiting NCT04831658 - A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma Phase 1/Phase 2
Recruiting NCT04899427 - Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma Phase 2